$CSRA {{ '2016-08-02T18:11:10+0000' | timeago}} • Announcement

$CSRA said it was awarded a new contract to provide multiple levels of IT support for the National Human Genome Research Institute (NHGRI). The new, single-award contract is valued at $17MM over a three-year period.

$CSRA {{ '2017-12-21T16:17:41+0000' | timeago}} • Announcement

$CSRA's BoD declared a quarterly dividend of $0.10 per share on its common stock. The dividend will be paid on Jan. 25, 2018 to stockholders of record at the close of business on Jan. 4, 2018.

$CSRA {{ '2017-11-07T22:28:13+0000' | timeago}} • Announcement

$CSRA's backlog of signed business orders at the end of 2Q18 was $17.7Bil, of which $2.7Bil was funded. On a sequential basis, total backlog was up 14%, while funded backlog was up 11% for the quarter.

$CSRA {{ '2017-11-07T22:25:57+0000' | timeago}} • Announcement

For FY18, $CSRA expects revenue to be in the range of $5-5.2Bil and adjusted diluted EPS in the range of $1.88-2.00 per share. Adjusted EBITDA for FY18 is expected in the range of $770-800MM, while free cash flow expectation is of $330-380MM.

$CSRA {{ '2017-11-07T22:19:23+0000' | timeago}} • Announcement

IT services provider $CSRA reported flat YoY earnings for 2Q18. Net income remained flat at $76MM or $0.46 per share, while revenue for the quarter increased marginally by 1% to $1.27Bil. On an adjusted basis, $CSRA declined 10% to $0.46 per share from $0.51 per share a year earlier.

$CSRA {{ '2017-11-07T21:56:25+0000' | timeago}} • Infographic

$CSRA CSRA Inc. Earnings AlphaGraphic: Q2 2018 Highlights

$CSRA {{ '2017-05-24T22:03:45+0000' | timeago}} • Webcast

$CSRA stated that regarding the drivers of revenue acceleration in 2H18, the company is seeing a healthy pipeline of new work. Additionally, on head count growth and utilization, $CSRA has seen steady labor utilization rates in recent quarters and expects the same moving forward.

$CSRA {{ '2017-05-24T21:53:24+0000' | timeago}} • Webcast

$CSRA expects quarterly revenue and earnings to step up through 2018, with 1Q18 being slightly below 4Q17, driven by the continued wind-downs of some contracts and equipment purchases pulled forward into 4Q17.

$CSRA {{ '2017-05-24T21:30:18+0000' | timeago}} • Webcast

$CSRA won $3.8Bil in new business in FY17, which the company believes should yield north of $700MM in annual revenue when fully ramped. In 4Q17, $CSRA had its highest number of hires to date, including large number of talented millenials attracted to next generation technology. The company expects this trend to strengthen in FY18.

$CSRA {{ '2017-05-24T20:48:55+0000' | timeago}} • Announcement

For 4Q17, $CSRA's operating cash flow was $50MM, and free cash flow was $62MM. "Our book-to-bill ratio of 1.1x marked the ninth straight quarter with bookings at or above revenue," said CEO Larry Prior.

$CSRA {{ '2017-05-24T20:46:30+0000' | timeago}} • Announcement

For FY18, $CSRA sees a revenue of $5.0-5.2Bil, adjusted EBITDA of $770-800MM and free cash flow of $330-380MM, generating an adjusted diluted earnings of $1.88-2.00 per share.

$CSRA {{ '2017-05-24T20:41:45+0000' | timeago}} • Announcement

Revenue for $CSRA fell 3% to $1.25Bil in 4Q17, as earnings moved up to $0.22 per diluted share from last year's loss of $0.44 a share. Net income attributable to stockholders was $37MM, up from a loss of $72MM, with bookings totaling $1.3Bil in the quarter.

$CSRA {{ '2017-02-07T22:23:12+0000' | timeago}} • Announcement

$CSRA lowered its FY17 revenue outlook to $4.96-5.01Bil from $5-5.2Bil and its adjusted EBITDA estimate to $857-867MM from $870-905MM. The company narrowed its FY17 adjusted EPS forecast to $1.98-2.02 from $1.91-2.04. $CSRA still predicts free cash flow of $300-350MM. The estimate for adjusted EBITDA and EPS assumes pension income of $92MM.

$CSRA {{ '2017-02-07T22:18:32+0000' | timeago}} • Announcement

$CSRA's bookings totaled $1.9Bil in 3Q17, representing a book-to-bill ratio of 1.5 times. The company's backlog of signed business orders at the end of 3Q17 was $15.8Bil, of which $2.7Bil was funded. Total backlog increased 3% compared to the pro forma backlog at the end of 3Q16.

$CSRA {{ '2017-02-07T22:16:15+0000' | timeago}} • Announcement

$CSRA reported a rise in 3Q17 earnings driven by higher revenue. Net income rose to $128MM or $0.76 per share from $51MM or $0.29 per share last year. Revenue grew 18% to $1.22Bil, as a result of merger with SRA International. Pro forma EPS remained unchanged at $0.48.

$CSRA {{ '2016-12-27T16:05:09+0000' | timeago}} • Announcement

$CSRA's subsidiary DynPort Vaccine Co. (DVC) received multiple-award, indefinite-delivery, indefinite-quantity (IDIQ) contract to manage variety of medical product development initiatives for National Institute of Allergy and Infectious Diseases (NIAID). DVC is one of 4 awardees to get IDIQ valued up to $159MM, with 10 years performance period.

$CSRA {{ '2016-12-21T18:03:40+0000' | timeago}} • Announcement

$CSRA received a task order valued at $744MM to provide a wide-range of services supporting the Command, Control, Communications, Computers, Intelligence, Surveillance and Reconnaissance (C4ISR) systems used by U.S. Army coalition forces around the world.

$CSRA {{ '2016-11-21T14:27:50+0000' | timeago}} • Announcement

$CSRA received a re-competed contract with the Department of Homeland Security's Office of Cybersecurity and Communications to provide a broad range of technical services and expertise. The single-award contract is valued at more than $52MM over a 4-year period.

$CSRA {{ '2016-11-09T22:15:34+0000' | timeago}} • Announcement

$CSRA still expects FY17 revenue of $5-5.2Bil and adjusted EPS of $1.91-2.04. The company maintained its 2017 adjusted EBITDA guidance of $870-905MM and free cash flow outlook of $300-350MM. The estimate for adjusted EBITDA and EPS assumes pension income of $96MM, consistent with amounts recorded in 1H17.

$CSRA {{ '2016-11-09T22:13:18+0000' | timeago}} • Announcement

$CSRA's bookings for 2Q17 totaled $2.4Bil, representing a book-to-bill ratio of 1.9x. The company's backlog of signed business orders at end of 2Q17 was $15.5Bil, of which $3Bil was funded. Total backlog increased 2% compared to pro forma backlog at end of 2Q16.

$CSRA {{ '2016-11-09T22:09:39+0000' | timeago}} • Announcement

Information technology services provider $CSRA reported a rise in 2Q17 earnings as merger with SRA International drove revenue higher by 30%. Net income rose to $76MM or $0.46 per share from $48MM or $0.35 per share last year. Revenue grew to $1.26Bil from $969MM. Adjusted EPS increased to $0.56 from $0.53.

Recent Transcripts

ORCL (Oracle Corporation)
Thursday, December 14 2017 - 10:00pm
CNFR (Conifer Holdings, Inc.)
Thursday, November 9 2017 - 1:30pm
COLL (Collegium Pharmaceutical, Inc.)
Wednesday, November 8 2017 - 9:30pm
Tuesday, November 7 2017 - 10:00pm
CHRS (Coherus Biosciences, Inc.)
Monday, November 6 2017 - 9:30pm
ICFI (ICF International Inc.)
Thursday, November 2 2017 - 8:30pm
CACI (CACI International Inc.)
Thursday, November 2 2017 - 12:30pm
CMPR (Cimpress N.V.)
Thursday, November 2 2017 - 11:30am
ACXM (Acxiom Corporation)
Wednesday, November 1 2017 - 9:00pm
CIGI (Colliers International Group Inc.)
Tuesday, October 31 2017 - 3:00pm
CIVB (Civista Bancshares, Inc.)
Friday, October 27 2017 - 7:00pm
MSFT (Microsoft Corporation)
Thursday, October 26 2017 - 9:30pm
GOOGL (Alphabet Inc.)
Thursday, October 26 2017 - 8:30pm
LLL (L-3 Communications Holdings Inc.)
Thursday, October 26 2017 - 3:00pm
FCN (FTI Consulting, Inc.)
Thursday, October 26 2017 - 1:00pm
ADS (Alliance Data Systems Corporation)
Thursday, October 19 2017 - 12:30pm
ORCL (Oracle Corporation)
Thursday, September 14 2017 - 9:00pm
CACI (CACI International Inc.)
Thursday, August 17 2017 - 12:30pm
CNFR (Conifer Holdings, Inc.)
Thursday, August 10 2017 - 12:30pm
Wednesday, August 9 2017 - 9:00pm

AlphaGraphics you may like